580 results about "Intrathecal" patented technology

A system and method for assessing the severity of medication errors associated with intravenous administration is provided. A harm index database includes harm index values for various parameters of medication administration. A medication administration device may access this database and assess the overall harm index for particular errors in order to provide appropriate alerts based on the severity of the error. Further, assessment of the harm index value may be used retrospectively to provide reports of event logs that include an overall harm index value associated with each alert.

The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

A coated filter bag for use in cold or hot drinks, in particular, a novel method for administration of pharmaceutical actives, supplemental nutrients, genetically derived materials, or other beneficial agents using a coated filter bag that includes at least one agent that solubilizes when in contact with liquid and is dispersed in the proper dosage amount into the liquid for oral consumption.

An oral dosage form comprises cromolyn sodium (sodium or disodium cromoglycate), and an acylated amino acid delivery agent.

Dry powder formulations of drugs such as antihistamine for nasal administration are provided where the drug is retained in the nasal cavity, and systemic side effects minimized or eliminated, through the selection of a narrow particle size range, between approximately 10 and 20 microns in diameter. In a preferred embodiment wherein the drug is an antihistamine, retention of the antihistamine at the nasal mucosa is improved and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced. By making a dry powder formulation of an antihistamine (e.g., azelastine) having an average particle size of between 10 and 20 microns, the antihistamine is restricted primarily to the desired target organ, the nasal mucosa. Because the active ingredient stays in the nasal region, a lower dose can be used to achieve the same desired effect. As demonstrated by the examples, this lower dose reduces the incidence of somnolence, and because the active ingredient remains at the target organ and does not accumulate in the back of the throat and mouth, this formulation does not impart a bitter taste.